Table 3b.
PFS | OS | |||
---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
TMB (log-scale) | 0.79 | 0.058 | 0.96 (0.7–1.3) | 0.802 |
ECOG PS | 1.74 (0.1–3.2) | 0.075 | 2.35 (1.2–4.7) | 0.015 |
≥2 vs. 0–1 | ||||
No. of metastatic sites | 1.66 (0.1–2.9) | 0.078 | 2.71 (1.4–5.2) | 0.002 |
≥3 vs. <3 | ||||
No. of prior therapies | NA | NA | 1.67 (0.9–3.0) | 0.087 |
≥3 vs. <3 |
PS, performance status; No., number; ICI, immune checkpoint inhibitor; NA, not applicable (not significant in univariate analysis); TMB, tumor mutation burden. Significant values highlighted in bold.